Tarrex Biopharma, a Xiamen drug discovery startup, has purchased a 33% stake in oncology company Aranda Pharma Ltd. of Finland, and the two companies will co-develop Aranda’s androgen receptor antagonist as a treatment for Castration Resistant Prostate Cancer (CRPC). Aranda’s AR antagonist has demonstrated efficacy in prostate cancer models that are resistant to current treatments. The amount of Tarrex’s investment in Aranda was not disclosed.
Help employers find you! Check out all the jobs and post your resume.
